innate-pharma.com-welcome to innate pharma

Données techniques du innate-pharma.com

Geo IP vous fournit comme la latitude, la longitude et l'ISP (Internet Service Provider) etc. informations. Notre service GeoIP a trouvé l'hôte innate-pharma.com.Actuellement, hébergé dans Italy et son fournisseur de services est IUNET BNET .

Latitude:	45.46427154541
Longitude:	9.189510345459
Pays:	Italy (it)
Ville:	Milan
Région:	Lombardia
ISP:	IUNET BNET

the related websites

domaine	Titre
innate-pharma.com	welcome to innate pharma \| innate pharma
ipsr.in	ipsr group of institution best college for b.pharma, m.pharma , d.pharma, manage
byclassier.com	by classier - innate sense of glamour
pharma5.ma	pharma 5 - la qualité du soin commence par l'accès aux soins pour tous \| pharma
firstwordpharma.com	pharma industry news and analysis - firstword pharma
harmonium-pharma.fr	harmonium pharma - radicati nel diabeteharmonium pharma
sgdgroup.com	sgd pharma, inspiring confidence - sgd-pharma
geistlich.fr	geistlich - pharma - france pharma
sgd-pharma.com	sgd pharma, inspiring confidence - sgd-pharma
searchlightpharma.com	searchlight pharma – searchlight pharma is a canadian-based specialty healthcare
merz.ch	home - merz pharma schweiz - merz pharma schweiz
idi-pharma.com	idi pharma
doc-pharma.fr	doc' pharma
h2pharma.fr	h3 pharma
ajcpharma.fr	ajc pharma

alternativesante.fr

curie.fr

Analyse d'en-tête HTTP

Les informations d'en-tête HTTP font partie du protocole HTTP que le navigateur d'un utilisateur envoie à appelé Apache contenant les détails de ce que le navigateur veut et acceptera de nouveau du serveur Web.

Content-Length:	8349
X-Drupal-Cache:	MISS
X-Content-Type-Options:	nosniff
Content-Language:	en
X-Powered-By:	PHP/7.0.30
Expires:	Sun, 19 Nov 1978 05:00:00 GMT
Vary:	Cookie,Accept-Encoding,User-Agent
Keep-Alive:	timeout=5, max=100
Server:	Apache
Last-Modified:	Sun, 10 Jun 2018 22:38:07 GMT
Connection:	Keep-Alive
Etag:	"1528670287-1"
Link:	; rel="canonical",; rel="shortlink"
Cache-Control:	public, max-age=3600
Date:	Sun, 10 Jun 2018 22:38:07 GMT
X-Frame-Options:	SAMEORIGIN
Content-Type:	text/html; charset=utf-8
Content-Encoding:	gzip
X-Generator:	Drupal 7 (http://drupal.org)

DNS

soa:	ns1.amen.fr. root.amen.fr. 2018011602 86400 7200 2592000 300
ns:	ns1.amen.fr. ns2.amen.fr.
ipv4:	IP:164.132.31.159 ASN:16276 OWNER:OVH, FR Country:FR
mx:	MX preference = 10, mail exchanger = mx1.innate-pharma.fr. MX preference = 20, mail exchanger = mx2.innate-pharma.fr.

HtmlToText

") ") skip to main content fr en toggle navigation profile leadership team supervisory board scientific advisory board founders history key figures key competencies science innate pharma, the innate immunity company immunity & immunotherapy bibliography pipeline monalizumab iph4102 iph5401 iph52 iph53 iph4301 iph61 anti-siglec-9 lirilumab monoclonal antibodies adc technology bispecific antibodies partnering investors regulated information & publications share information investor kit corporate governance financial calendar investor relations news & events press releases events innate in the news career welcome to innate pharma scroll about innate pharma innate pharma s.a. is a clinical-stage biotechnology company with a focus on discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients see company profile headlines annual general meeting 2018 the annual general meeting will take place on may 29, 2018, in marseille, france. download the documents aacr 2018 innate pharma presented new data at the aacr annual meeting, april 14-18, in chicago, including preliminary data suggesting promising anti-tumor activity of the combination of monalizumab and cetuximab in patients with platinum pretreated scchn. see posters 2017 financial statements innate pharma releases its 2017 financial statements on march 8, 2018. see the press release download area corporate presentation | q2 2018 download r&d day march 2018 download reference document 2017 download activity report 2016 download latest news clinical data from ongoing phase i dose escalation and expansion study of monalizumab and imfinzi® (durvalumab) in colorectal cancer patients presented at 2018 asco annual meeting june 4, 2018 outcome of annual general meeting of may 29, 2018 may 29, 2018 preliminary data from a phase i dose escalation and expansion study of monalizumab and imfinzi® (durvalumab) show anti-tumor activity in colorectal cancer patients may 17, 2018 all press releases upcoming events bryan garnier oncology day | paris, france june 13, 2018 6th antibody industrial symposium | montpellier, france june 25, 2018 to june 26, 2018 afssi connexions | marseille, france july 2, 2018 to july 3, 2018 all events contact location site map legal info profile leadership team supervisory board scientific advisory board founders history key figures key competencies science innate pharma, the innate immunity company immunity & immunotherapy bibliography pipeline monalizumab iph4102 iph5401 iph52 iph53 iph4301 iph61 anti-siglec-9 lirilumab monoclonal antibodies adc technology bispecific antibodies partnering investors regulated information & publications share information investor kit corporate governance financial calendar investor relations news & events press releases events innate in the news career follow us stay in touch subscribe to our newsletter contact us 117, avenue de luminy - bp 30191 13 009 marseille france +33 (0)4 30 30 30 30

Analyse PopURL pour innate-pharma.com

http://www.innate-pharma.com/en/pipeline-technologies
http://www.innate-pharma.com/en/investors/investor-kit
http://www.innate-pharma.com/en/news-events/innate-news
http://www.innate-pharma.com/en/pipeline/iph52-first-class-anti-cd39-checkpoint-inhibitors-program
http://www.innate-pharma.com/en/news-events/press-releases/preliminary-data-phase-i-dose-escalation-and-expansion-study-monalizumab-and-imfinzir-durvalumab-show-anti-tumor-activity-colorectal-cancer-patients
http://www.innate-pharma.com/en/legal-info
http://www.innate-pharma.com/en/iph4102-first-class-anti-kir3dl2-mab
http://www.innate-pharma.com/sites/default/files/180308_rd_day_-_presentation_-_finale.pdf
http://www.innate-pharma.com/en/investors
http://www.innate-pharma.com/en/news-events/press-releases/outcome-annual-general-meeting-may-29-2018
http://www.innate-pharma.com/sites/default/files/gb_innate_ra2016.pdf
http://www.innate-pharma.com/en/profile/scientific-advisory-board
http://www.innate-pharma.com/#main-content
http://www.innate-pharma.com/en/contact
http://www.innate-pharma.com/en/news-events/press-releases

Informations Whois

Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;

Domain Name: INNATE-PHARMA.COM
Registry Domain ID: 25328571_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.networksolutions.com
Registrar URL: http://networksolutions.com
Updated Date: 2017-04-04T04:07:51Z
Creation Date: 2000-04-20T13:21:41Z
Registry Expiry Date: 2018-04-20T13:21:41Z
Registrar: Network Solutions, LLC.
Registrar IANA ID: 2
Registrar Abuse Contact Email: abuse@web.com
Registrar Abuse Contact Phone: +1.8003337680
Domain Status: ok https://icann.org/epp#ok
Name Server: NS1.AMEN.FR
Name Server: NS2.AMEN.FR
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-08-30T23:37:01Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR Network Solutions, LLC.

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =innate-pharma.com

  PORT 43

  TYPE domain
RegrInfo
DOMAIN

  NAME innate-pharma.com

  CHANGED 2017-04-04

  CREATED 2000-04-20

STATUS
ok https://icann.org/epp#ok

NSERVER

  NS1.AMEN.FR 81.88.63.33

  NS2.AMEN.FR 81.88.63.39

  REGISTERED yes

Go to top

innate-pharma.com rapport : Visitez le site